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ABSTRACT 
Objective: Intrathecal drug delivery (ITDD) is commonly used for intractable pain 
management. A paucity of good quality studies in chronic non-cancer patients and concerns 
over increased dosages has focused interest on different modes of administration. The aim 
of this international multicentre randomised double-blind crossover trial was to compare the 
efficacy of the same daily dose of drugs administered by intermittent boluses versus simple 
continuous infusion.  
Methods: Eligible patients implanted with a programmable ITDD device were randomised to 
receive two weeks of either intermittent boluses or a simple continuous flow in period 1, 
followed by a crossover to the alternative mode of administration. The primary outcome 
measure was the Patients’ Global Impression of Change (PGIC) scale. 
Results: The mean proportion of positive responders (at least “minimally improved”) was 
38.4% in the Continuous condition versus 37.3% in the Bolus (difference in proportions = 
1.1%; 95% CI, -21.8 to 24.0%; P=0.93). The mean PGIC in the Continuous condition was 
3.8 versus 3.9 in the Bolus (mean difference = -0.1; -0.6 to 0.4; P=0.72). Exploratory 
analyses revealed a tendency for the mean proportion of positive responders to be higher at 
low vs. high flow rates for both bolus and continuous administrations. Two patients were 
withdrawn from the study due to adverse events during the Bolus phase: both with 
symptoms of increased pain, and one patient with additional symptoms of numbness and 
urinary retention. 
Conclusion: The mean PGIC and proportion of positive responders was not substantially 
different after intermittent bolus versus continuous administration. 
 
Keywords: bolus infusion, continuous infusion, intrathecal drug delivery, patients’ global 
impression of change, randomised crossover trial 
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INTRODUCTION 
The use of implanted devices for the intrathecal administration of drugs to relieve intractable 
pain has been practiced for nearly four decades [1]. The advantage of the intrathecal route is 
that, compared to systemic administration, an equivalent or better analgesic effect can be 
obtained with lower doses and therefore less severe side effects [2]. In addition, the direct 
access to the intrathecal space allows the use of drugs that cannot be administered by 
another route because of either systemic inactivation or inability to cross the blood brain 
barrier. Yet, despite increasing popularity, there is a paucity of high quality clinical studies, 
resulting in an ongoing controversy regarding the efficacy of intrathecal drug delivery (ITDD). 
More recently, clinicians have become interested in the influence of the flow profile on the 
treatment efficacy. Two blinded randomised controlled studies have shown that for a given 
dose, changing the daily flow rate did not significantly affect the clinical effect whether in 
patients with severe spasticity [3] or intractable pain [4]. An earlier clinical observation 
suggested that a small dose of bupivacaine given as a “fast” bolus produces better analgesia 
than a large dose given continuously (slowly) [5]. This is consistent with the finding of a 
previous double-blinded RCT that showed no benefit of adding bupivacaine to IT opioids 
administered as a continuous infusion, although the maximum daily dose of bupivacaine in 
this study was 8 mg/day compared to an average daily dose of 10 mg/day in other studies 
that demonstrated efficacy of adding bupivacaine to IT opioids [6]. 
Animal experiments conducted using flows similar to those delivered by programmable 
intrathecal infusion device have shown that intrathecal drug distribution into the 
cerebrospinal fluid (CSF) and spinal cord is limited when (low) clinically used infusion rates 
are utilised [7]. Increasing the flow rate from 20 microl/hr to 1000 microl/hr and the 
administration of the drugs as bolus resulted in a wider distribution of the study drugs 
baclofen and bupivacaine in the CSF and spinal cord parenchyma. The findings were the 
same regardless of the drug used. The author concluded that the position of the catheter tip 
is crucial when drugs are administered by slow continuous flow and that continuous 
infusions are associated with a higher risk of intrathecal granulomas, presumably because 
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the spinal cord and the meninges are exposed to higher drug concentrations. It has been 
suggested that use of the lowest effective dose and concentration of intrathecal opioids, 
intermittent bolus dosing, and adjuvant therapy with nonopioid analgesic medications may all 
prevent granuloma formation [8-10]. 
The aim of this study was to compare the efficacy of the same daily dose of drugs 
administered by intermittent boluses compared to simple continuous infusion on the Patients’ 
Global Impression of Change (PGIC) scale. We postulate that administration of the same 
drugs by intermittent boluses will result in wider drug spread in the CSF and spinal cord 
parenchyma resulting in better analgesia. 
 
METHODS 
Study design 
The study is an international multicentre randomised double blind crossover study. Two 
different modes of administration were evaluated, (1) the usual daily dose fractionated into 6 
intermittent boluses and (2) the same dose administered as a simple continuous flow. Each 
flow pattern was maintained for two weeks in a double blind randomised crossover design. 
Safety and efficacy were evaluated by means of patient and assessor-based evaluations. 
Recruitment took place in two English centres (The James Cook University Hospital, South 
Tees Hospitals NHS Foundation Trust; Russells Hall Hospital, Dudley Group of Hospitals 
NHS Foundation Trust) and two Swiss centres (EHC-Hôpital De Morges; Luzerner 
Kantonsspital). 
The study was reviewed and approved by the ethics committee NRES Committee East 
Midlands – Northampton, reference: 10/H0402/54. The study was registered with 
ISRCTN61628624. All patients provided written informed consent prior to randomisation. 
 
Study population 
Patients were eligible for inclusion if they were 18 years of age or older, implanted with a 
programmable ITDD device for the management of non-cancer pain and having achieved 
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stable pain relief on a continuous flow. In addition, all eligible patients would be receiving 
one of morphine, clonidine or bupivacaine in isolation or a combination of any two of these 
intrathecal medications. 
Exclusions included the use of a non-programmable ITDD pump, a patient-controlled mode 
(PTM device) or other bolus mode modality, patients receiving intrathecal ziconotide, 
patients with poor cognitive ability, severe limitation in function or mobility and refusing to 
participate in the study. 
In this study all patients were implanted with a SynchroMed®II pump (Medtronic, 
Minneapolis USA). 
 
Interventions 
Intermittent Boluses Group (IB) 
Subjects randomised to receive intermittent boluses underwent pump programming by the 
unblinded investigator in order to deliver a minimum background infusion rate of 48mcl/day 
as a continuous background infusion (pump programming does not allow for intermittent 
boluses alone). The remainder of the total daily dose was fractionated into six intermittent 
maximum speed (delivered over the shortest time period allowable by the ITDD) boluses 
delivered automatically at 4-hourly intervals. The total daily dose remained unchanged, i.e. 
was the same as before entering the study. 
Continuous Infusion Group (CI) 
Patients randomised to simple continuous infusion continued to receive the same dose of 
drugs at the same flow rate. 
 
Study procedure 
Eligible patients were randomised sequentially to receive either intermittent boluses or 
continuous infusion in a 1:1 ratio using a central randomisation system. The randomisation 
sequence was prepared by the trial statistician (AB) and allocation concealment maintained 
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until completion of baseline data recording. At this time the allocation of the patient was 
revealed by e-mail to the (blinded) study coordinator. 
The clinical team was split into two groups: the unblinded team, which provided the clinical 
care for the patients, and the blinded team, which was responsible for study data collection. 
These groups were strictly adhered to and no crossover of clinical staff occurred. 
Programming of the intermittent boluses takes considerably longer time than simple 
continuous infusion and patients would be aware of this. To aid the blinding of the patient 
and blinded clinical team members, the programming took place in a separate room from the 
patient. After a period of approximately 15 minutes the unblinded clinical team member 
returned to the patient to update the intrathecal pump. 
To ensure patients’ safety during the trial phases of intermittent bolus (IB) and continuous 
infusion (CI), the concentration and dosing ranges for the intrathecal medications were 
carefully considered. The safe maximum daily doses for both the IB and CI groups were as 
follows: 
 Morphine sulphate solution (preservative free) was administered at a maximum 
concentration of 40 mg/ml and at a maximum total daily dose of 10 mg/day; 
 Clonidine hydrochloride was given at a maximum concentration of 2000 mcg/ml and 
a maximum total daily dose of 500 mcg/day; 
 Bupivacaine hydrochloride was given at a maximum concentration of 30 mg/ml and a 
maximum total daily dose of 15mg/day. 
Following pump programming patients were observed in a clinical area for 5 hours with 2 
hourly vital signs and reported side effects were noted. The patients were contacted the day 
after the programming to either IB or CI to ascertain if any adverse events had occurred. 
Each group received intermittent boluses or continuous infusion for a period of two weeks. A 
two-week period was deemed appropriate as it allowed for one week of stabilisation, with the 
outcomes being collected during the second week. Subjects initially randomised to group IB 
would crossover for a two-week period to group CI and vice versa. At the end of the study, 
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patients were asked whether they preferred, the initial or the second programming; the ITDD 
was then programmed according to their choice. If patients could not choose between the 
two programmes, a continuous infusion was programmed. 
 
Outcome measures 
The study primary outcome parameter was the PGIC [11]. The PGIC assesses the patient’s 
self-rated overall change since the start of the study in a seven-point Likert scale. Patients 
rate their change as very much improved, much improved, minimally improved, no change, 
minimally worse, much worse, or very much worse. The PGIC was completed at the end of 
each two-week period. The PGIC is a recommended core outcome measure of global 
improvement with treatment for use in chronic pain clinical trials [12]. 
Secondary outcomes included: pain assessed using a 100 mm visual analogue scale (VAS) 
ranging from 0 (no pain) to 100 (worst possible pain) collected by diary for five days prior to 
each visit [13], health-related quality-of-life using the EQ-5D-3L [14], adverse events and 
patient programme preference. We also asked the blinded study nurse to guess the therapy 
group between IB and CI to test the strength of the blinding (observer guess). VAS and EQ-
5D-3L were collected at baseline (pre-randomisation), and at the end of each two-week 
period. Adverse events could be reported at any time during the study period. Patient 
programme preference and observer guess of the group were assessed at the end of the 
study. 
 
Data analysis 
The sample size estimation is linked directly to the analysis strategy, and was conducted 
using SAS® statistical software (Version 9.1, SAS Institute Inc., Cary, NC, USA) according 
to procedures outlined by Senn [15]. We defined the minimum clinically important difference 
(MCID) for the primary outcome – the PGIC scale - as a treatment effect (between-treatment 
difference) of half a standard deviation (SD). An effect size of 0.5 SDs is regarded as a good 
indication of the MCID for patient reported outcomes of this type. Indeed, this effect size was 
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found to be the mean MCID in a review [16], with the authors noting the remarkable 
consistency of this MCID across various methodologies and clinical conditions. With 
2P=0.05 and 80% power the required sample size was 34 patients. 
For the primary outcome of PGIC we performed two analyses: a responder analysis [17] and 
an analysis of PGIC as a continuous variable. For the former, a responder was defined as a 
patient reporting at least ‘minimally improved’ on the 7-point scale (i.e. a score of 1, 2, or 3). 
The PGIC as a continuous variable and the secondary outcomes (pain VAS, EQ-5D index, 
EQ VAS) were analysed using a conventional within-subjects model, accounting for the 
period effect. All analyses were conducted using Stata statistical software (v. 13.1; Stata 
Corp. College Station, Texas, USA). Patients with missing outcome data for one of the two 
periods were included in the analysis via application of a generalised linear mixed model 
using restricted maximum likelihood [18]. 
In a secondary analysis, we explored the effect of flow rate on both the primary outcome 
(responder analysis) and pain VAS via a flow rate × treatment interaction term. All mean 
effects are presented with 95% confidence intervals. Treatment effects were estimated at the 
10th (3.1 mcl/hour) and 90th (18.5 mcl/hour) centiles for flow rate. 
 
RESULTS 
Study enrolment, allocation to the IB and CI groups, and follow-up of study participants are 
summarised in the flow diagram shown in Figure 1. Forty-six patients were screened and a 
total of 32 patients were randomised (IB group: 16; CI group: 16). Patient data at baseline is 
presented in Table 1. The median (IQR) for bolus percentage of total daily dose was 10.0 
(7.7 to 13.7)%. 
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Figure 1 CONSORT flow diagram 
 
Primary Outcome 
Twenty-eight patients completed both bolus and continuous treatments. A further two 
patients completed one of the two periods and were included in the analysis, as their data 
help recover some of the missing within-subject information from the between-subject 
information. The intention-to-treat analysis is therefore based on 30/32 patients. 
The estimated mean proportion of positive responders to treatment was 38.4% in the 
Continuous condition versus 37.3% in the Bolus. The difference in proportions (Continuous-
Bolus) was therefore 1.1% (95% CI, -21.8 to 24.0%; P=0.93). As a continuous variable, the 
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mean PGIC in the Continuous condition was 3.8 versus 3.9 in the Bolus. The mean 
difference was -0.1 (-0.6 to 0.4; P=0.72). 
 
Table 1. Patient characteristics at baseline (N=32 unless stated) 
Variable  
Sex (M: F) 18: 14 
Age (years) 55.3 (9.9) 
Pain VAS (mm) [n=27] 49 (20) 
EQ-5D index (median [IQR]) 0.390 (0.072, 0.620) 
EQ VAS (mm) 52 (19) 
Morphine dose (mg/day) [n=23] 2.6 (1.7) 
Bupivacaine dose (mg/day) [n=10] 3.8 (2.2) 
Clonidine dose (mcg/day) [n=16] 164.8 (169.4) 
Flow rate (mcl/hr) 11 (9) 
Catheter tip position [n=27]  
Thoracic level (T10 to T12) 16 (59%) 
Thoracic level (other) 3 (11%) 
Lumbar level 8 (30%) 
Data are mean (SD) unless stated. IQR, interquartile range. 
 
Secondary Outcomes 
Pain (VAS) and health-related quality-of-life (EQ-5D-3L) 
Secondary outcome results for pain using the VAS and health-related quality-of-life using the 
EQ-5D-3L are shown in Table 2. No substantial differences between treatments were 
observed for the secondary outcomes. 
 
Table 2. Treatment effects on secondary outcomes 
Outcome Continuous mean Bolus mean Difference (95% CI) 
Pain VAS (mm) 47.9 49.2 -1.3 (-4.9 to 2.3) 
EQ-5D index 0.385 0.388 -0.003 (-0.100 to 0.094) 
EQ VAS (mm) 49.1 50.2 -1.1 (-6.3 to 4.1) 
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Patient Preferences 
Of the 28 patients completing both bolus and continuous treatments, 14 (50%) expressed a 
preference for Continuous, 12 (43%) for Bolus, and 2 (7%) had no preference. 
 
Observers guess of the group 
Observer guess of the group was recorded for 26 patients that completed both bolus and 
continuous treatments. The observers guessed the group sequence correctly for 65% 
(17/26) of the patients (95% CI, 47% to 84%; P=0.06, against a hypothesised proportion of 
50%). 
 
Effect of flow rate 
The Treatment × Flow rate interactions (Table 3) reveal that the mean proportion of positive 
responders (at least slightly improved on the PGIC) was greater at low flow rates within each 
treatment condition, with considerable uncertainty in the estimates revealed by the width of 
the confidence intervals. However, there was no substantial effect of flow rate on the bolus 
vs. continuous comparison. Similarly, pain is greater on average at higher vs. lower flow 
rates but with no substantial difference between treatments (Table 4). 
 
Table 3. Interaction of flow rate with treatment effect: Estimated proportion of responders on 
the Patient Global Impression of Change (%) 
Flow rate Bolus Continuous Difference (95% CI) 
3.1 mcl/hour 49.6 48.2 1.4 (-29.2 to 31.9) 
18.5 mcl/hour 20.4 25.4 -5.0 (-40.0 to 30.0) 
 
Difference between 
flow rates by treatment 
 
29.1 
(-9.1 to 67.3) 
 
22.7 
(-15.8 to 61.3) 
 
 
Table 4. Interaction of flow rate with treatment effect: Effect on Pain VAS 
Flow rate Bolus Continuous Difference (95% CI) 
3.1 mcl/hour 43.2 41.6 1.6 (-4.2 to 7.5) 
18.5 mcl/hour 57.1 56.4 0.7 (-7.8 to 9.1) 
 
Difference between 
flow rates by treatment 
 
-13.9 
(-33.9 to 6.2) 
 
-14.8 
(-32.4 to 2.7) 
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Adverse events 
A total of 16 adverse events during bolus infusion and 12 during continuous infusion, 
potentially related with the treatment, were recorded during the study period (Table 5). One 
patient withdrew during the Bolus phase because of an emergency surgery for iliac aneurism 
(unrelated to the study) and one patient withdrew after initial programming (no reason 
provided). Two patients were withdrawn from the study due to adverse events during the 
Bolus phase. The patients presented with symptoms of increased pain, and one of the 
patients also presented with numbness and urinary retention. One of the patients was 
receiving morphine 5mg/day and clonidine 125 mcg/day at a flow rate of 10.42 mcl/hr, and 
the other patient morphine 2.3 mg/day and clonidine 17.9 mcg/day at a flow rate of 4.17 
mcl/hr. Both patients were programmed to continuous infusion and made a full recovery 
following discontinuation of the study. 
 
Table 5. Adverse events reported after each treatment phase 
Adverse event Bolus (N=32) Continuous (N=32) 
Numbness 4 (13) 0 
Burning sensations 1 (3) 0 
Increased pain 4 (13) 4 (13) 
Nausea & vomiting 2 (6) 3 (9) 
Headache 3 (9) 2 (6) 
Hypertension 1 (3) 1 (3) 
Urinary retention 1 (3) 0 
Sweating 0 2 (6) 
Other (unrelated) 5 (16) 1 (3) 
Numbers represent N (%). 
 
DISCUSSION 
This international multicentre randomised double blind crossover trial is the first study 
powered to detect differences between bolus and continuous intrathecal administrations. No 
substantial differences between treatments for the primary and secondary outcomes were 
observed. This finding is in contrast with previous studies reporting improvements in 
patients’ pain perception using intrathecal bolus administration [5,19]. Indeed, Buchser and 
colleagues [5] observed a patient who did not respond to a significant dose of bupivacaine 
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added to a continuous administration of morphine and clonidine but reported a reduction on 
the VAS from 70mm to less than 20mm following a bolus of 0.5 mg of bupivacaine. Recently, 
a small (n=10) randomised double blind crossover trial reported that patients receiving 40% 
of the daily dose as four boluses and the remaining 60% as a slow and constant background 
infusion obtained statistically significant decrease in pain scores when compared to 
continuous infusion [19]. A placebo effect cannot be excluded as a reason for this finding. 
Although the study claims that the patients were blinded to treatment administration, it is not 
clear how the programming of the pumps was performed. The patients would be aware of 
the time required to programme a continuous infusion and would notice a longer duration to 
reprogram the pump. Furthermore, responders to bolus administration tended to have lower 
pain scores in the first week of treatment a trend that was not statistically significant but may 
also suggest a placebo effect. 
The CSF has limited capacity to distribute intrathecal morphine, baclofen, and bupivacaine 
away from the catheter tip [7,20]. It has been demonstrated that higher flow rates and bolus 
administration leads to a wider dispersion of intrathecal bupivacaine and baclofen [7]. 
However, the bolus / infusion ratio used in the Bernards study was increased 50 fold to a 
much higher rate (1000 microL/hr over five minutes every hour for eight hours) than what 
could be used in our patient group. An assessment of a similarly substantially different speed 
of delivery between continuous infusion and bolus could shed some light into possible 
differences in effect of the modes of administration, although it may not be feasible with 
current intrathecal pump technology. Bernards also observed that at 1000 microL/hr there is 
no difference in dispersion between continuous infusion and hourly boluses of 1000 microL 
which may explain the absence of differences in the current study between continuous 
infusion and bolus infusion for the same amount of the drug. Drug distribution in the CSF has 
also been found to be affected by body position [21]. Patients for this trial were excluded if 
they had severe limitation in function and mobility, which could have limited the drug 
distribution during daytime and subsequent patient-reported outcomes. 
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Catheter tip positioning and flow rate used are important factors to consider when trialling 
patients for ITDD. However, several patients that respond to the trial period then fail to 
obtain good pain relief following implantation of the pump requiring adjustments to the 
intrathecal medication. This may occur because the trial is usually performed using a bolus 
dose and following implantation the administration mode is changed to a continuous 
infusion. The drug distribution during continuous infusion may not be sufficient to produce 
therapeutic drug concentrations in spinal cord segments distant from the catheter tip [20]. 
The use of higher flow rates and consequent wider dispersion of the drugs, may lead to an 
insufficient drug concentration in the appropriate spinal cord segments resulting in increase 
in pain severity and decrease in EQ-5D index scores [3,4]. Adequate or inadequate 
placement of the catheter tip may help to explain why studies investigating changes in flow 
rate or bolus administration may have failed to observe significant results. Additionally, 
change in response after implantation could in part be caused by a placebo effect during the 
trial or patient increased expectations based on response during the trial period. 
In our study there was no substantial effect of flow rate on the Bolus vs. Continuous 
infusions with differences between treatments being trivial at both low and high flow rates. 
However, mean differences between flow rates within each treatment condition were 
substantial, with a larger proportion of responders on the PGIC and lower pain ratings at low 
vs. high flow rates. The comparisons between low and high flow rates within each treatment 
condition are not statistically significant, but the investigations of interaction between flow 
rates with treatment effects were exploratory, as this study had low power to detect small, 
clinically relevant interactions. There is good evidence of a substantial main effect for flow 
rate that needs to be confirmed in a larger definitive study. We chose the PGIC as a primary 
outcome measure for this study rather than the VAS as the PGIC allows the patient the 
ability to express a balanced view on both pain relief and side effects, whereas the VAS only 
addresses pain relief. It is therefore possible that the trend for an effect for low flow rate may 
well be related to a smaller impact of side effects in lower flow group rather than improved 
pain scores in the PGIC. The device used in the study mandated a minimal background flow 
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rate of 48mcl/day, thereby imposing a greater restriction on bolus size in patients with lower 
flow rates. It is possible that such a restriction has led to a lower side effect rate and an 
accompanying improvement in PGIC in this group. 
The observers guessed the group sequence correctly for 65% (17/26) of the patients. This 
rate of correct guesses was mainly due to observers being able to correctly interpret 
episodes related to medication side effects, i.e. sensory and motor changes resulting from 
boluses of bupivacaine and nausea related to opioids. 
The main strengths of this study were its international multicentre randomised double blind 
crossover trial design using the patients as their own controls. However, there are some 
limitations that merit mention. A small number of patients were included, although the study 
was powered to detect a minimum clinically important difference for the PGIC. The use of 
daily activity monitoring or alternative physical function measures could have contributed to 
capture changes occurring due to modifications in the mode of intrathecal administration. 
The drugs used were heterogeneous as patients were receiving different drug combinations. 
Drug distribution within the CSF is affected by baricity [21]. The assessment of bolus infusion 
in patients using a single drug (e.g. baclofen) would allow a more objective assessment of 
treatment effect. Patients with a PTM device were not eligible for participation in this study 
as the bolus administration was scheduled; it is possible that by being able to control the 
timings of the boluses, participants in the study could have presented improved outcomes. 
Primary outcome data were missing from one period for two patients (one for Bolus and one 
Continuous) and from both periods for a further two patients. To explore the potential impact 
of these missing data, we conducted a simple ‘extreme-case’ sensitivity analysis favouring 
the continuous treatment (the treatment with the larger mean proportion of responders). This 
approach involved the assumption of a beneficial response for the three missing Continuous 
treatment periods and a non-beneficial response for the three missing Bolus treatment 
periods. The estimated mean proportion of positive responders to treatment of 43.8% in the 
Continuous condition versus 34.4% in the Bolus. The difference in proportions (Continuous-
Bolus) was therefore 9.4% (95% CI, -12.7 to 31.4%; P=0.39). The fact that the difference 
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between treatments in the proportion of responders remains trivial in the sensitivity analysis 
shows that the primary analysis is robust in the face of a small proportion of missing data. 
In conclusion, there were no substantial differences in a continuous versus a bolus infusion 
on PGIC, either as a proportion of positive responders to treatment or as a continuous 
variable. No substantial differences were observed for the secondary outcomes. Due to the 
heterogeneity of drug combinations that were used in the patients included in this study and 
the potential effect of baricity on drug distribution, it would be important to investigate the 
effect of bolus administration in a patient population receiving a single intrathecal drug. 
Although the study had not been powered for this purpose, an exploratory analysis indicated 
a trend towards a greater proportion of positive responders (improved PGIC) and lower pain 
scores with low flow rates. This finding merits further investigation. 
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